Comparative Pharmacology
Head-to-head clinical analysis: ALLERNAZE versus PROMETHAZINE W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERNAZE versus PROMETHAZINE W CODEINE.
ALLERNAZE vs PROMETHAZINE W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at histamine H1 receptors, preventing histamine-mediated symptoms such as itching, sneezing, and vasodilation.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits nociceptive transmission; promethazine is a phenothiazine derivative with H1-receptor antagonism, anticholinergic, and antiemetic effects.
5 mg orally once daily at bedtime, maximum 10 mg per day.
10 mL (1 mg codeine, 6.25 mg promethazine per 5 mL) orally every 4-6 hours as needed for cough. Maximum: 60 mL per day. Do not exceed 5 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. Clinical context: Allows for twice-daily dosing in allergic rhinitis; steady-state reached in 2-3 days.
Promethazine: 10-19 hours (terminal). Codeine: 2.5-3.5 hours (terminal); prolonged in renal impairment.
Primarily renal (70-80% as unchanged drug and metabolites), with approximately 5-10% biliary/fecal elimination.
Promethazine: renal (70% as metabolites, <1% unchanged), fecal (20-30%). Codeine: renal (90%, of which 5-10% unchanged, rest as metabolites), fecal (minor).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic